Healios K.K Dirección

Dirección controles de criterios 2/4

El CEO de Healios K.K es Hardy Kagimoto, nombrado en Feb 2012, tiene una permanencia de 12.75 años. posee directamente un 31.88% de las acciones de la empresa, con un valor de ¥5.63B. La antigüedad media del equipo directivo y de la junta directiva es de 8.8 años y 6.8 años, respectivamente.

Información clave

Hardy Kagimoto

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	12.8yrs
Participación del CEO	31.9%
Permanencia media de la dirección	8.8yrs
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Is Healios K.K (TSE:4593) Using Too Much Debt?

May 31

CEO

Hardy Kagimoto (48 yo)

12.8yrs

Permanencia

Dr. Tadahisa S. Kagimoto, also known as Hardy, MD, serves as Chairman, Chief Executive Officer and President of Aqumen Biopharmaceuticals, K.K. He served as Director of Athersys, Inc. since June 18, 2018 u...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Tadahisa S. Kagimoto	Chairman & CEO	12.8yrs	sin datos	31.88% ¥ 5.6b
Richard P. Kincaid	CFO, Executive Officer & Internal Director	5.3yrs	sin datos	0.21% ¥ 36.7m
Masanori Sawada	Executive VP	9.7yrs	sin datos	sin datos
Kouichi Tamura	Exec. Off.	8.8yrs	sin datos	sin datos
Yoshinari Matsuda	Managing Director	8.7yrs	sin datos	sin datos

8.8yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4593 es experimentado (8.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Tadahisa S. Kagimoto	Chairman & CEO	12.8yrs	sin datos	31.88% ¥ 5.6b
Richard P. Kincaid	CFO, Executive Officer & Internal Director	6.8yrs	sin datos	0.21% ¥ 36.7m
Glenn J. Gormley	Independent Outside Director	2.8yrs	sin datos	sin datos
Seigo Kashii	Independent External Director	6.8yrs	sin datos	0.00022% ¥ 38.9k
Hideki Takeda	Auditor	7.8yrs	sin datos	0.56% ¥ 98.8m
Yuko Yogo	Independent Outside Director	2.8yrs	sin datos	sin datos

6.8yrs

Permanencia media

66.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 4593 se considera experimentada (6.8 años de antigüedad promedio).

Healios K.K Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Healios K.K., Annual General Meeting, Mar 27, 2024

Healios K.K. Announces Management Changes

High number of new directors

Less than half of directors are independent

Healios K.K., Annual General Meeting, Mar 25, 2022

Healios K.K. Announces Announcement of Change in Management

Recent updates

Healios K.K. Announces Agreement with the FDA on Pivotal, Global Phase 3 "REVIVE-ARDS" Clinical Trial

Price target increased by 17% to JP¥340

Healios K.K. to Report Q3, 2024 Results on Nov 13, 2024

Consensus EPS estimates upgraded to JP¥29.83 loss

Healios K.K. to Report Q2, 2024 Results on Aug 13, 2024

Is Healios K.K (TSE:4593) Using Too Much Debt?

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Healios K.K. to Report Q1, 2024 Results on May 13, 2024

Consensus revenue estimates increase by 64%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Consensus revenue estimates fall by 24%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Healios K.K., Annual General Meeting, Mar 27, 2024

Healios K.K. and Procellcure Inc. Announce Start of Ards Clinical Trial in Japan

Healios K.K. announced that it expects to receive ¥2.2600715 billion in funding

Healios K.K. and Its Wholly Owned Subsidiary ProcellCure Inc. Announce Submission of ARDS Clinical Trial Notification in Japan

Consensus EPS estimates upgraded to JP¥56.76 loss

Healios K.K. to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings released: JP¥9.98 loss per share (vs JP¥12.31 loss in 3Q 2022)

Consensus revenue estimates increase by 130%

New minor risk - Market cap size

HEALIOS K.K. Conducts the Treasure Study to Investigate the Safety and Efficacy of HLCM051

Healios K.K. to Report Q3, 2023 Results on Nov 14, 2023

HEALIO K.K. Provides its Innovative eNK Platform for A Novel Research Study on Metastatic Uveal Melanoma At Thomas Jefferson University in Philadelphia

Price target increased by 11% to JP¥845

Second quarter 2023 earnings released: JP¥10.37 loss per share (vs JP¥32.62 loss in 2Q 2022)

Healios K.K. Announces Use of 3D Bioreactor-Based Manufacturing Method Produced Product for ARDS

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Healios K.K. to Report Q2, 2023 Results on Aug 14, 2023

Healios K.K. Announces Submission of Clinical Trial Notification for RPE Tail Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

First quarter 2023 earnings released: JP¥11.52 loss per share (vs JP¥26.47 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to JP¥60.13 loss

Price target decreased by 19% to JP¥762

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Healios K.K. Announces Management Changes

Forecast to breakeven in 2025

High number of new directors

Healios K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: JP¥12.31 loss per share (vs JP¥34.86 loss in 3Q 2021)

Healios K.K. announced that it has received ¥100.0316 million in funding from SATAKE Corporation

HEALIOS Announces Results from the TREASURE Study

Healios K.K. announced that it expects to receive ¥100.0316 million in funding from SATAKE Corporation

Healios K.K. NK Cells Demonstrate Anti-Tumor Effect in Lung Cancer Patient-Derived Cancer Organoids

Healios K.K. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

First half 2022 earnings released: JP¥59.11 loss per share (vs JP¥36.60 loss in 1H 2021)

Healios K.K. to Report Q2, 2022 Results on Aug 10, 2022

Healios K.K. Reports Top-Line Results from Treasure Study for Ischemic Stroke

First quarter 2022 earnings released: JP¥26.47 loss per share (vs JP¥19.92 loss in 1Q 2021)

Price target decreased to JP¥2,760

Less than half of directors are independent

Healios K.K. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to JP¥2,760

Healios K.K. Announces Completion of 365 Days Post-Administration Follow Up for TREASURE Study for Patients with Ischemic Stroke

Healios K.K. Provides Progress Update in Relation to Application for Approval for HLCM051 for ARDS

Full year 2021 earnings released: JP¥93.36 loss per share (vs JP¥107 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Healios K.K., Annual General Meeting, Mar 25, 2022

Healios K.K. Announces Announcement of Change in Management

Third quarter 2021 earnings released: JP¥34.78 loss per share (vs JP¥29.02 loss in 3Q 2020)

HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the ONE-BRIDGE Study

First quarter 2021 earnings released: JP¥19.92 loss per share (vs JP¥29.02 loss in 1Q 2020)